|
Report No. : |
329145 |
|
Report Date : |
25.06.2015 |
IDENTIFICATION DETAILS
|
Name : |
HIKAL LIMITED |
|
|
|
|
Registered
Office : |
717/718, Maker
Chambers V, 7th Floor, Nariman Point, Mumbai – 400021, Maharashtra |
|
Tel. No.: |
91-22-22301801 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2015 |
|
|
|
|
Date of
Incorporation : |
08.07.1988 |
|
|
|
|
Com. Reg. No.: |
11–048028 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.164.400 Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
L24200MH1988PTC048028 |
|
|
|
|
TIN No.: |
Not Available |
|
|
|
|
IEC No.: |
Not Available |
|
|
|
|
TAN No.: [Tax Deduction & Collection
Account No.] |
MUMH07537F /
BRDH00497A |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACH0383A |
|
|
|
|
Legal Form : |
A Public Limited Liability Company.
The Company’s Shares are Listed on the Stock Exchanges. |
|
|
|
|
Line of Business
: |
The Company is engaged in the manufacturing of various
chemical intermediates, specialty chemicals, active pharma ingredients and
contract research activities. |
|
|
|
|
No. of Employees
: |
1101 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (50) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an
established company having satisfactory track. The company
possesses a favorable financial profile marked by adequate networth base along
with modest working capital intensive operations. Management has
witnessed a decent revenue as well as higher profitability and cash accruals
leading to improvement in debt protection metrics during FY 2014. Trade relations are fair. Business is active. Payment terms are
reported as usually correct. The company can be considered for business dealings at usual trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EXTERNAL AGENCY RATING
|
Rating Agency Name |
ICRA |
|
Rating |
Long Term Rating = BBB |
|
Rating Explanation |
Moderate degree of safety and moderate
credit risk |
|
Date |
March 2015 |
|
Rating Agency Name |
ICRA |
|
Rating |
Short Term Rating = A2 |
|
Rating Explanation |
Strong degree of safety and low credit risk |
|
Date |
March 2015 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter in
the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2013.
INFORMATION DECLINED BY
|
Name : |
Mr. Sham Vinayak Wahalekar |
|
Designation : |
Chief Financial Officer |
|
Contact No.: |
91-22-22301801 |
|
Date : |
24.06.2015 |
LOCATIONS
|
Registered
Office / Corporate Office : |
717/718, Maker
Chambers V, 7th Floor, Nariman Point, Mumbai – 400 021,
Maharashtra, India |
|
Tel. No.: |
91-22-22301801 |
|
Fax No.: |
91-22-22833913 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Head Office : |
6, Nawab
Building, 327, Dr. D. N. Road, Fort, Mumbai – 400 001, Maharashtra, India. |
|
Tel. No.: |
91-22-22301801 |
|
Fax No.: |
91-22-22833913 |
|
|
|
|
Administrative
Office : |
Great Eastern
Chambers, 6th Flore, Sector 11, CBD – Belapur, Navi Mumbai – 400 614,
Maharashtra, India |
|
Tel. No.: |
91-22-27574276 /
27574336 / 27574991 / 30973100 |
|
Fax No.: |
91-22-27574277 |
|
Email : |
|
|
|
|
|
|
603, Great Eastern Chambers, Mumbai, Maharashtra, India. |
|
|
|
|
Plant Location
: |
Tel No. : 91-2646-302 100
|
|
|
|
|
Overseas
Office |
Located at
|
DIRECTORS
As on 31.03.2014
|
Name : |
Mr. Jai Hiremath |
|
Designation : |
Chairman and Managing Director |
|
|
|
|
Name : |
Mr. Sameer J. Hiremath |
|
Designation : |
President and Joint Managing Director |
|
|
|
|
Name : |
Mr. Baba N. Kalyani |
|
Designation : |
Director |
|
|
|
|
Name : |
Dr. Peter Pollak |
|
Designation : |
Director |
|
|
|
|
Name : |
Dr. Axel Kleemann |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Wolfgang Welter |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Prakash V. Mehta |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Shivkumar M. Kheny |
|
Designation : |
Director |
|
|
|
|
Name : |
Mrs. Sugandha J. Hiremath |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Amit Kalyani |
|
Designation : |
Director |
KEY EXECUTIVES
|
Name : |
Mr. Sham. V. Wahalekar |
|
Designation : |
Company Secretary/ Chief Financial Officer |
|
|
|
|
Audit Committee : |
|
SHAREHOLDING PATTERN
As on 31.03.2015
|
Category of
Shareholder |
No.
of Shares |
Percentage
of Holding |
|
(A) Shareholding of Promoter and Promoter Group |
|
|
|
|
|
|
|
|
7863400 |
9.57 |
|
|
48115110 |
58.53 |
|
|
550000 |
0.67 |
|
|
550000 |
0.67 |
|
|
56528510 |
68.77 |
|
|
|
|
|
Total shareholding of Promoter and Promoter Group (A) |
56528510 |
68.77 |
|
(B) Public Shareholding |
|
|
|
|
|
|
|
|
7931465 |
9.65 |
|
|
19500 |
0.02 |
|
|
100500 |
0.12 |
|
|
3877340 |
4.72 |
|
|
11928805 |
14.51 |
|
|
|
|
|
|
727677 |
0.89 |
|
|
|
|
|
|
5017378 |
6.10 |
|
|
725430 |
0.88 |
|
|
7272700 |
8.85 |
|
|
63315 |
0.08 |
|
|
121550 |
0.15 |
|
|
6800000 |
8.27 |
|
|
287835 |
0.35 |
|
|
13743185 |
16.72 |
|
Total Public shareholding (B) |
25671990 |
31.23 |
|
Total (A)+(B) |
82200500 |
100.00 |
|
(C) Shares held by Custodians and against which Depository Receipts
have been issued |
0 |
0.00 |
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
|
0 |
0.00 |
|
Total (A)+(B)+(C) |
82200500 |
0.00 |

BUSINESS DETAILS
|
Line of Business : |
The Company is engaged in the manufacturing of various
chemical intermediates, specialty chemicals, active pharma ingredients and
contract research activities. |
|
|
|
|
Products : |
Chemical |
|
|
|
|
Brand Names : |
-- |
|
|
|
|
Agencies Held : |
-- |
|
|
|
|
Exports : |
Not Divulged |
|
|
|
|
Imports : |
Not Divulged |
|
|
|
|
Terms : |
|
|
Selling : |
Not Divulged |
|
|
|
|
Purchasing : |
Not Divulged |
PRODUCTION STATUS – NOT AVAILABLE
GENERAL INFORMATION
|
Suppliers : |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Customers : |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
No. of Employees : |
1101 (Approximately) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Bankers : |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Facilities : |
Long Term Borrowings (AS ON 31.03.2014) Nature of Security i) Terms loans from banks and financial institutions are secured by hypothecation of plant & machinery, first charge on the immovable properties and second charge on current assets situated at Taloja, Panoli and Bangalore ii) Deferred payment liability relates to certain vehicles and other equipments and is secured by way of first charge on the said assets.
Short Term Borrowings Nature of Security
and terms of repayment for secured/unsecured borrowings
|
|
|
|
|
Auditors : |
|
|
Name : |
BSR and Company Chartered Accountants |
|
|
|
|
Legal Advisor : |
Malvi Ranchoddas
and Company |
|
|
|
|
Memberships : |
-- |
|
|
|
|
Collaborators : |
-- |
|
|
|
|
Subsidiary
Companies (AS ON 31.03.2014) : |
|
|
|
|
|
Enterprises over
which key management personnel and their relatives exercise significant
influence (AS ON 31.03.2014) : |
|
CAPITAL STRUCTURE
As ON 31.03.2015
Authorised Capital : Not Available
Issued, Subscribed & Paid-up Capital : Rs. 164.400
Million
As on 31.03.2014
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
25000000 |
Equity Share |
Rs.10/- Each |
Rs.250.000
Million |
|
5000000 |
Cumulative
Redeemable Preference shares |
Rs.100/- Each |
Rs.500.000 Million |
|
|
Total |
|
Rs.750.000
Million |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
16440100 |
Equity Shares |
Rs.10/- Each |
Rs.164.401
Million |
Reconciliation of the shares outstanding at
the beginning and at the end of the reporting period
|
Equity Shares |
Number
in Million |
Rs. In Million |
|
At the beginning of the year |
16.440 |
164.400 |
|
Outstanding at the end of the year |
16.440 |
164.400 |
Terms/rights attached
to equity shares
The company has only one class of equity shares having a par value of Rs.10/- per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.
During the year ended March 31, 2014 the amount of per share dividend recognized as distributions to equity shareholders was Rs.4.50/- (2013: Rs.2.50/-). In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.
Details of
shareholders holding more than 5% shares in the company
|
Name of
Shareholder |
Number
of Shares |
% holding |
|
Kalyani Investment Company Limited |
5.160 |
31.36 |
|
Shri Badrinath Investment Private Limited |
2.650 |
16.15 |
|
Shri Rameshwara Investment Private Limited |
1.310 |
7.96 |
|
International Finance Corporation |
1.360 |
8.27 |
|
Sugandha J Hiremath |
1.290 |
7.84 |
|
Reliance Capital Trustee Company Limited |
1.12 |
6.82 |
FINANCIAL DATA
[all figures are
in Rupees Million]
ABRIDGED BALANCE
SHEET
|
SOURCES
OF FUNDS |
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
|
|
|
|
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
164.400 |
164.400 |
164.400 |
|
(b) Reserves & Surplus |
5454.700 |
4894.650 |
4348.080 |
|
(c) Money received against
share warrants |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share Application money
pending allotment |
0.000 |
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
5619.100 |
5059.050 |
4512.480 |
|
|
|
|
|
|
(3) Non-Current Liabilities |
|
|
|
|
(a) long-term borrowings |
2014.400 |
2548.220 |
2196.270 |
|
(b) Deferred tax liabilities
(Net) |
300.800 |
324.900 |
86.250 |
|
(c) Other long term
liabilities |
0.000 |
0.000 |
0.000 |
|
(d) long-term provisions |
117.100 |
109.200 |
96.620 |
|
Total
Non-current Liabilities (3) |
2432.300 |
2982.320 |
2379.140 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a) Short term borrowings |
2310.100 |
2155.480 |
2602.830 |
|
(b) Trade payables |
1371.300 |
1310.850 |
1128.410 |
|
(c) Other current liabilities |
1315.200 |
1001.910 |
1236.280 |
|
(d) Short-term provisions |
181.300 |
197.900 |
60.440 |
|
Total
Current Liabilities (4) |
5177.900 |
4666.140 |
5027.960 |
|
|
|
|
|
|
TOTAL |
13229.300 |
12707.510 |
11919.580 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a) Fixed Assets |
|
|
|
|
(i) Tangible assets |
7010.100 |
6441.410 |
6607.570 |
|
(ii) Intangible Assets |
|
0.000 |
0.000 |
|
(iii) Capital work-in-progress |
|
611.670 |
485.430 |
|
(iv) Intangible assets under
development |
|
0.000 |
0.000 |
|
(b) Non-current Investments |
31.300 |
31.270 |
31.270 |
|
(c) Deferred tax assets (net) |
0.000 |
0.000 |
0.000 |
|
(d) Long-term Loan and Advances |
879.400 |
677.190 |
704.160 |
|
(e) Other Non-current assets |
0.000 |
0.000 |
0.000 |
|
Total
Non-Current Assets |
7920.800 |
7761.540 |
7828.430 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a) Current investments |
0.000 |
0.000 |
0.000 |
|
(b) Inventories |
3139.500 |
3112.930 |
2570.330 |
|
(c) Trade receivables |
1279.700 |
887.370 |
846.290 |
|
(d) Cash and cash equivalents |
137.000 |
276.880 |
154.050 |
|
(e) Short-term loans and
advances |
409.200 |
657.390 |
514.410 |
|
(f) Other current assets |
43.100 |
11.400 |
6.070 |
|
Total
Current Assets |
5008.500 |
4945.970 |
4091.150 |
|
|
|
|
|
|
TOTAL |
12929.300 |
12707.510 |
11919.580 |
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
8718.600 |
8292.110 |
6604.170 |
|
|
|
Other Income |
15.700 |
340.550 |
63.080 |
|
|
|
TOTAL (A) |
8734.300 |
8632.660 |
6667.250 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Cost of materials consumed |
5239.100 |
3878.100 |
2725.980 |
|
|
|
Changes in inventories of finished goods and work-in-progress |
(48.700) |
(119.840) |
(115.480) |
|
|
|
Employee benefits expense |
892.000 |
790.190 |
701.760 |
|
|
|
Other expenses |
811.000 |
1691.610 |
1447.980 |
|
|
|
Exceptional Items |
0.000 |
179.250 |
484.330 |
|
|
|
TOTAL (B) |
6893.400 |
6419.310 |
5244.570 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
1840.900 |
2213.350 |
1422.680 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
600.400 |
680.040 |
598.780 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
1240.500 |
1533.310 |
823.900 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
641.800 |
550.230 |
490.620 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
598.700 |
983.080 |
333.280 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
193.500 |
342.270 |
78.240 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
405.200 |
640.810 |
255.040 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
NA |
2123.120 |
1946.170 |
|
|
|
|
|
|
|
|
|
Less |
APPROPRIATIONS |
|
|
|
|
|
|
|
Interim Dividend on Equity Shares |
NA |
32.880 |
0.000 |
|
|
|
Proposed Dividend on Equity Shares |
NA |
41.100 |
41.100 |
|
|
|
Tax on proposed dividend |
NA |
12.570 |
6.990 |
|
|
|
Transfer to General Reserve |
NA |
100.000 |
30.000 |
|
|
BALANCE CARRIED
TO THE B/S |
NA |
2577.380 |
2123.120 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
|
|
|
|
|
|
|
Export Earnings |
NA |
7056.900 |
5818.080 |
|
|
TOTAL EARNINGS |
NA |
7056.900 |
5818.080 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
NA |
2302.350 |
1925.550 |
|
|
|
Capital Goods |
NA |
13.710 |
14.310 |
|
|
|
Stores & Spares |
NA |
22.400 |
7.460 |
|
|
TOTAL IMPORTS |
NA |
2338.460 |
1947.320 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
4.93 |
38.98 |
15.52 |
|
CURRENT MATURITIES
OF LONG TERM DEBT DETAILS
|
Particulars |
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
Current Maturities of Long term borrowings |
NA |
737.240 |
1128.410 |
|
Cash generated from operations |
NA |
NA |
NA |
KEY RATIOS
|
PARTICULARS |
|
31.03.2015 |
31.03.2014 |
31.03.2013 |
|
Net Profit Margin (PAT/Sales) |
(%) |
4.65 |
7.73 |
3.86 |
|
|
|
|
|
|
|
Operating Profit Margin (PBDIT/Sales) |
(%) |
21.11 |
26.69 |
21.54 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
4.64 |
8.15 |
2.92 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.11 |
0.19 |
0.07 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Debt /Networth) |
|
0.77 |
1.08 |
1.31 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
0.97 |
1.06 |
0.81 |
STOCK
PRICES
|
Face Value |
Rs.2/- |
|
Market Value |
Rs.129.60/- |
FINANCIAL ANALYSIS
[all figures are
in Rupees Million]
DEBT EQUITY RATIO
|
Particular |
31.03.2013 |
31.03.2014 |
31.03.2015 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Share Capital |
164.400 |
164.400 |
164.400 |
|
Reserves & Surplus |
4348.080 |
4894.650 |
5454.700 |
|
Money received against share
warrants |
0.000 |
0.000 |
0.000 |
|
Share Application money pending allotment |
0.000 |
0.000 |
0.000 |
|
Net
worth |
4512.480 |
5059.050 |
5619.100 |
|
|
|
|
|
|
long-term borrowings |
2196.270 |
2548.220 |
2014.400 |
|
Short term borrowings |
2602.830 |
2155.480 |
2310.100 |
|
Total
borrowings |
4799.100 |
4703.700 |
4324.500 |
|
Debt/Equity
ratio |
1.064 |
0.930 |
0.770 |

YEAR-ON-YEAR GROWTH
|
Year
on Year Growth |
31.03.2013 |
31.03.2014 |
31.03.2015 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
6604.170 |
8292.110 |
8718.600 |
|
|
|
25.559 |
5.143 |

NET PROFIT MARGIN
|
Net
Profit Margin |
31.03.2013 |
31.03.2014 |
31.03.2015 |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
6604.170 |
8292.110 |
8718.600 |
|
Profit |
255.040 |
640.810 |
405.200 |
|
|
3.86% |
7.73% |
4.65% |

LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check list by
info agents |
Available in
Report (Yes/No) |
|
1 |
Year of establishment |
Yes |
|
2 |
Constitution of the entity -Incorporation
details |
Yes |
|
3 |
Locality of the entity |
Yes |
|
4 |
Premises details |
No |
|
5 |
Buyer visit details |
-- |
|
6 |
Contact numbers |
Yes |
|
7 |
Name of the person contacted |
Yes |
|
8 |
Designation of contact person |
Yes |
|
9 |
Promoter’s background |
Yes |
|
10 |
Date of Birth of Proprietor / Partners /
Directors |
Yes |
|
11 |
Pan Card No. of Proprietor / Partners |
No |
|
12 |
Voter Id Card No. of Proprietor / Partners |
No |
|
13 |
Type of business |
Yes |
|
14 |
Line of Business |
Yes |
|
15 |
Export/import details (if applicable) |
No |
|
16 |
No. of employees |
Yes |
|
17 |
Details of sister concerns |
Yes |
|
18 |
Major suppliers |
No |
|
19 |
Major customers |
No |
|
20 |
Banking Details |
Yes |
|
21 |
Banking facility details |
Yes |
|
22 |
Conduct of the banking account |
-- |
|
23 |
Financials, if provided |
Yes |
|
24 |
Capital in the business |
Yes |
|
25 |
Last accounts filed at ROC, if applicable |
Yes |
|
26 |
Turnover of firm for last three years |
Yes |
|
27 |
Reasons for variation <> 20% |
-- |
|
28 |
Estimation for coming financial year |
No |
|
29 |
Profitability for last three years |
Yes |
|
30 |
Major shareholders, if available |
Yes |
|
31 |
External Agency Rating, if available |
No |
|
32 |
Litigations that the firm/promoter
involved in |
-- |
|
33 |
Market information |
-- |
|
34 |
Payments terms |
No |
|
35 |
Negative Reporting by Auditors in the
Annual Report |
No |
UNSECURED LOAN:
|
Particulars |
31.03.2014 Rs.
In Million |
31.03.2013 Rs.
In Million |
|
LONG TERM
BORROWINGS |
|
|
|
Term loans from banks & others |
42.500 |
58.250 |
|
Deferred sales tax liability |
2.660 |
3.720 |
|
SHORT TERM
BORROWINGS |
|
|
|
Inter corporate deposits |
|
|
|
From related parties |
36.450 |
59.45 |
|
From others |
135.000 |
445.500 |
|
Total |
216.610 |
566.920 |
BACKGROUND (AS ON
31.03.2014)
The Company was incorporated as a public limited Company on July 8, 1988 having its registered office at 717/718, Maker Chamber V, Nariman Point, Mumbai 400 021. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities.
The Company is operating in the crop protection and pharmaceuticals space.
INDEX OF CHARGE:
|
S.NO. |
CHARGE ID |
DATE OF CHARGE
CREATION/MODIFICATION |
CHARGE AMOUNT
SECURED |
CHARGE HOLDER |
ADDRESS |
SERVICE REQUEST
NUMBER (SRN) |
|
1 |
10557450 |
17/03/2015 * |
750,000,000.00 |
STANDARD CHARTERED BANK |
112, SERENITY, 3RD FLOOR, EAST WING,, KORAMANGALA |
C50136928 |
|
2 |
10532057 |
21/10/2014 * |
480,000,000.00 |
INTERNATIONAL FINANCE CORPORATION |
2121 PENNSYLVANIA N.W., WASHINGTON D.C. 20433, WA |
C34422733 |
|
3 |
10518631 |
26/08/2014 |
400,000,000.00 |
THE RATNAKAR BANK LIMITED |
SHAHUPURI,KOLHAPUR,, KOLHAPUR, MAHARASHTRA - 41600 |
C19630920 |
|
4 |
10512641 |
31/07/2014 |
600,000,000.00 |
STANDARD CHARTERED BANK |
112, SERENITY, 3RD FLOOR, EAST WING,, KORAMANGALA |
C14868863 |
|
5 |
10460074 |
30/10/2013 |
200,000,000.00 |
ICICI BANK LIMITED |
ICICI BANK TOWERS, BANDRA KURLA COMPLEX,, MUMBAI, |
B89482756 |
|
6 |
10458011 |
25/10/2013 |
250,000,000.00 |
KOTAK MAHINDRA BANK LIMITED |
36-38A, NARIMAN BHAVAN, 227,D,, NARIMAN POINT,, M |
B88695663 |
|
7 |
10381047 |
09/12/2014 * |
150,000,000.00 |
ADITYA BIRLA FINANCE LIMITED |
INDIAN RAYON COMPOUND,, VERAVAL, GUJARAT - 362266, |
C53610671 |
|
8 |
10345467 |
21/03/2013 * |
300,000,000.00 |
ICICI BANK LIMITED |
ICICI BANK TOWERS, BANDRA KURLA COMPLEX BANDRA EA |
B72588262 |
|
9 |
10340869 |
21/03/2013 * |
300,000,000.00 |
EXPORT IMPORT BANK OF INDIA |
CENTRE ONE BUILDING, WORLD TRADE CENTRE COMPLEX,, |
B72125412 |
|
10 |
10338703 |
27/02/2012 |
150,000,000.00 |
YES BANK LIMITED |
9TH FLOOR, NEHRU CENTRE, DISCOVERY OF INDIA,, DR. |
B33491242 |
* Date of charge modification
FIXED ASSETS:
·
Land
·
Building
·
Plant and Machinery
·
Computer
·
Vehicles
·
Furniture and Fixture
NEWS:
HIKAL APPROVES SUB DIVISION OF EQUITY
SHARES
Hikal Limited has informed BSE that the Board of Directors of the Company at its meeting held on December 17, 2014, have transacted the following business:- Approved a proposal to sub-divide one Equity Share of the face value of Rs. 10/- each fully paid-up in the Equity Share Capital of the Company in to 5 (five) Equity Shares of the face value of Rs. 2/- each fully paid-up and carry out consequential amendments to the existing Clause V of the Memorandum of Association and Clause 3 of the Articles of Association of the Company.
HIKAL PHARMA RECEIVES
US FDA APPROVAL
Hikal Limited has informed BSE regarding "Hikal's Pharmaceutical Manufacturing Site in Gujarat, India received US FDA Approval". Hikal's Pharmaceutical received US FDA Approval for its pharmaceutical intermediates and active pharma ingredients manufacturing site located in Jigani, Bengaluru in Karnataka state.
HIKAL COMPLETES EDQM
AUDIT AT ITS BANGALORE FACILITY
Hikal Limited has informed BSE regarding "Hikal Completed successful EDQM
Audit of its Bangalore facility". Hikal has successfully completed an EDQM
inspection at its manufacturing facility at Bangalore, India, recently.
PRESS RELEASE
HIKAL SETS UP NEW
PILOT PLANT, API MANUFACTURING UNIT AND A KILO LAB
- July 26, 2006
Mumbai, July 26, 2006: Hikal Limited, has announced the commissioning of a new Pilot Plant at Taloja, a new API manufacturing unit at Bangalore and a cGMP kilo lab at Jigani. The facilities, set up at a cost of Rs. 50 crore, will help Hikal significantly enhance its capabilities to become the preferred outsourcing partner for the global life sciences companies.
A new pilot plant at Taloja has been set up to manufacture an agrochemical product for a global chemicals company. The pilot plant will start operations in August 2006 and a full-scale multi-purpose agrochemical plant is expected to be commissioned by 2008.
Hikal has set up a new API manufacturing unit in Bangalore that will manufacture a new veterinary drug for a global pharmaceutical company. The multi-product API plant is expected to start full-scale production by end-2007.
The company has set a new cGMP Kilo Lab at Jigani in Bangalore. The new facilities will enable Hikal to offer the complete range of outsourcing services to global life science companies through various stages of the product development cycle.
Jai Hiremath, Vice Chairman and Managing Director, Hikal said, “In the last few years, the need to outsource for the global life science majors has increased considerably, and outsourcing is moving from being just a tactical option to a more strategic one. Hikal will continue to expand and strengthen our capabilities to garner a larger pie of the multi-billion dollar opportunity.”
Mumbai headquartered Hikal Limited has a 2005-2006 turnover
of Rs 2417.000 Million with a 24 percent growth. Net profit for the year stood
at Rs.414.000 Million, a 21.4 percent growth from Rs 341.000 Million in
2004-2005. Revenues from the pharmaceutical division stood at Rs.834.000
Million, growing at 68 percent while the agrochemical division had revenues of
Rs.1470.000 Million, showing a 7 percent growth.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or investigation
registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.63.67 |
|
UK Pound |
1 |
Rs.100.50 |
|
Euro |
1 |
Rs.71.31 |
INFORMATION DETAILS
|
Information
Gathered by : |
PPT |
|
|
|
|
Analysis Done by
: |
KIN |
|
|
|
|
Report Prepared
by : |
KVT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL
CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILITY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
YES |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
DEFAULTER
|
|
|
|
--RBI |
YES/NO |
NO |
|
--EPF |
YES/NO |
NO |
|
|
|
|
|
TOTAL |
|
50 |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NB |
NEW BUSINESS |
||
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.